Small-cell lung cancer (SCLC): New positive data on PM1183 sees a response rate of 36% as single agent #ESMO17

da Salute H24 — 12 settembre 2017 alle 10:52


PharmaMar has presented during the European Society for Medical Oncology congress (ESMO), held in Madrid, positive results of PM1183 (lurbinectedin) in a cohort of 36 patients as monotherapy in patients with advanced and relapsed small-cell lung cancer (SCLC). Continua »

AntonioCaperna

Scrivi un commento